Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) dropped 1.8% on Tuesday after an insider sold shares in the company. The stock traded as low as $55.76 and last traded at $55.86. Approximately 12,367,363 shares changed hands during trading, a decline of 40% from the average daily volume of 20,724,897 shares. The stock had previously closed at $56.86.
Specifically, insider Michael Chi sold 5,100 shares of the firm's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $56.00, for a total value of $285,600.00. Following the completion of the sale, the insider now owns 256,580 shares of the company's stock, valued at $14,368,480. This trade represents a 1.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on HIMS shares. Bank of America raised their price target on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. Needham & Company LLC increased their target price on Hims & Hers Health from $61.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, June 4th. Leerink Partners boosted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Finally, Citigroup reiterated a "sell" rating and set a $30.00 price objective (up previously from $25.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $38.00.
Get Our Latest Report on HIMS
Hims & Hers Health Stock Performance
The firm has a market capitalization of $12.73 billion, a PE ratio of 128.66 and a beta of 2.09. The stock has a fifty day moving average price of $43.29 and a 200-day moving average price of $37.67.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The business had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm's revenue was up 110.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.05 earnings per share. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Hims & Hers Health
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geneos Wealth Management Inc. acquired a new position in shares of Hims & Hers Health during the first quarter worth $30,000. Blume Capital Management Inc. raised its stake in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares during the last quarter. UMB Bank n.a. raised its stake in Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after buying an additional 933 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Hims & Hers Health in the first quarter worth about $41,000. Finally, Larson Financial Group LLC grew its stake in shares of Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock worth $42,000 after acquiring an additional 458 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Recommended Stories
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
